• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats

    2017-02-27 05:54:23ViktoriaBekusovaVasilyPatsanovskiiAlexanderNozdrachevAlexandrTrashkovMargaritaArtemenkoVladimirAnisimovDepartmentofPhysiologyStPetersburgStateUniversityStPetersburg978RussiaPavlovInstituteofPhysiologyRussianAcademyofSciencesS
    Cancer Biology & Medicine 2017年1期

    Viktoria V. Bekusova, Vasily M. Patsanovskii, Alexander D. Nozdrachev,, Alexandr P. Trashkov, Margarita R. Artemenko, Vladimir N. AnisimovDepartment of Physiology, St. Petersburg State University, St. Petersburg 978, Russia;I.P.Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 990, Russia;Deparment of Experimental Pharmacology, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, The Russian Academy of Sciences, St. Petersburg 9, Russia;Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg 97758, Russia

    Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats

    Viktoria V. Bekusova1, Vasily M. Patsanovskii2, Alexander D. Nozdrachev1,2, Alexandr P. Trashkov3, Margarita R. Artemenko3, Vladimir N. Anisimov41Department of Physiology, St. Petersburg State University, St. Petersburg 197183, Russia;2I.P.Pavlov Institute of Physiology, Russian Academy of Sciences, St. Petersburg 199034, Russia;3Deparment of Experimental Pharmacology, I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, The Russian Academy of Sciences, St. Petersburg 194223, Russia;4Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St. Petersburg 197758, Russia

    Effects of two doses of the anti-diabetic drug, metformin (MF), on hormonal and metabolic levels of serum of non-diabetic male Wistar rats with 1,2-dimethylhydrazine (DMH)-induced colon tumor adenocarcinomas were studied. Carcinogenesis in the animals was also observed. Rats with DMH-induced colon adenocarcinomas had elevated levels of serum glucose, insulin, insulinlike growth factor-1, total cholesterol, triglycerides, catalase, malonic dialdehyde, glycated hemoglobin, aspartate aminotransferase, and alanine aminotransferase and decreased hemoglobin. Treatment with two doses of MF normalized majority of these changes in DMH-treated rats, whereas the drug was ineffective in rats without DMH treatment. The only exception was the decreased triglyceride levels in MF-treated rats. A 100 mg/kg dose of MF increased DMH-induced exophytic colon carcinomas and decreased endophytic tumors compared with untreated rats. Moreover, both MF doses increased DMH-induced and highly differentiated tumors and decreased the invasiveness of colon carcinomas compared with rats provided with DMH and water. Therefore, effects of MF on metabolic homeostasis are critical for preventing colon cancer.

    Colon cancer; prevention; 1,2-dimethylhydrazine; metformin; rat

    Introduction

    Colorectal cancer (CRC) is the third most common malignancy in humans worldwide; more than one million new cases occur annually1. Age is a leading CRC risk factor. More than 90% of CRC cases occur in people aged over 50, and approximately 75% of the cases are diagnosed in people older than 65. Furthermore, risks starting at 40 years of age increase sharply at 50 and double each decade until age 802. Hyperinsulinemia and obesity are key factors in cancer pathogenesis, including CRC3-6. The chemical carcinogen, 1, 2-dimethylhydrazine (DMH), has been widely used for induction of colon cancer. Regardless of mode of administration, DMH specifically induces tumors within thedescending colon of rats and some mouse strains, and resulting histopathologies are similar to those observed in human sporadic colon tumors7,8. Meanwhile, the antidiabetic biguanide, metformin (MF), lowers elevated insulin levels in type 2 diabetes3,9, significantly reduces various cancer risks in humans with the condition, and prevents tumor development in numerous rodent tissues and organs10,11. Furthermore, MF inhibits some chemically induced colon carcinogenesis in diabetic, obese12, and nondiabetic rats13. In this work, we showed the inhibitory effects of MF on DMH-induced colon carcinogenesis in nondiabetic rats. Such effects mainly involve the normalizing influence of MF on hormonal and metabolic homeostases.

    Material and methods

    Animals

    Male Wistar rats aged 2 months were bred at the Animal Laboratory of the I.P. Pavlov Institute of Physiology. Six toseven rats were kept in T3-type cages under a standard light/dark regimen (12 h light: 12 h darkness) at (22±2)°C and received standard laboratory PK-120 (Laboratorkorm, Russia)14and tap water ad libitum.

    Animals were checked daily by animal care personnel and weekly by a veterinarian. The weights were measured weekly as well. The study was conducted per the regulations for ensuring humane treatment of animals under the approval of the Committee on Animal Research of N.N. Petrov Research Institute of Oncology.

    Chemicals

    DMH was provided by Sigma Chemical Co., St. Lois, MO, USA and kept at –20°C. MF (MF HCl, Siophor) was purchased from Berlin-Chemie, Menarini Group, Germany.

    Experiment 1

    A total of 58 male Wistar rats with 2-month-old were randomly subdivided into 6 groups. A total of 24 rats in groups 1–3 were not exposed to carcinogens, whereas 34 rats from groups 4–6 were administered with 5 subcutaneous DMH injections weekly at a single dose of 21 mg/kg of body weight (calculated as a base). In this regimen, carcinogens induced colon tumors in majority of rats7. DMH was ex tempore dissolved in normal saline and neutralized with sodium bicarbonate (pH 7.0). Starting from the first carcinogen injection, groups 1 and 4 were provided with 1 mL tap water via intragastric gavage, whereas groups 2 and 5 were administered daily with MF (100 mg/kg) via gavage. Groups 3 and 6 were given MF (300 mg/kg) dissolved in 1 mL tap water. This treatment was concluded 2 months after the first DMH injection. The experiment was finalized six months after the first carcinogen injection. After being sacrificed by ether vapor, rats were decapitated, and blood samples were collected in plastic vessels without anticoagulants. After letting the samples stand for 30 min at room temperature, they were centrifuged (30 min at 1200 g) and then kept at –20°C until biochemical analyses. Metabolic parameters were assessed in blood serum. Glucose concentration was electrochemically estimated via an express analyzer (i-STAT, Abbot) that uses CG8+ cartridges. Total cholesterol, triglyceride, hemoglobin, and malonic dialdehyde (MDA) concentrations, and Cu, Zn-superoxide dismutase (SOD), catalase, alaninaminotransferase (ALT), and aspartataminotransferase (AST) activities were processed using Stat Fax 3300 analyzer and commercial reagent kits following the manufacturers’ instructions. Vascular endothelial growth factor (VEGF), insulin, and insulin-like growth factor (IGF-1) concentrations were assessed using enzyme-linked immunosorbent assay using Cusabio and R&B Systems reagent kits per standard procedures. Glycated hemoglobin was estimated using high performance liquid chromatography.

    Experiment 2

    A total of 24 male Wistar rats with 2-month-old were randomly subdivided into three groups and exposed to DMH and the same two doses of MF, as in Experiment 1. Experiment 2 was finalized six months after the first carcinogen injection. After being sacrificed using ether vapor, rats were autopsied by longitudinally opening the intestines. Tumor position and size were recorded7. After histological processing, tissues were embedded in paraffin. Histological sections measuring 3 μm thick were stained with hematoxylin-eosin and microscopically examined; in the experimental group, examination was performed as blind process. Tumors were classified per International Agency for Research on Cancer recommendations15.

    Statistical analysis

    Experimental results were statistically processed following variation statistics using Statistica-10. All data were expressed as mean ± standard error (Figures 1 and 2) or confidence interval for the standard deviation (Table 1). The significance of discrepancies was defined according to Chi-square analysis between experimental and control groups (Table 1). Differences in estimated parameters among the groups were assessed using non-parametric criterion of Mann-Whitney U test (Figures 1 and 2)16. P<0.01 and 0.05 were considered as significant.

    Results

    Effect of MF on DMF-induced hormonal and metabolic disturbances in male rats

    MF treatment failed to influence weight gain in both non-(groups 2 and 3) and DMH-exposed rats (groups 5 and 6). Thus, MF did not significantly affect weight gain between non- and DMH-exposed groups (data not shown). Twomonth administration of both doses of MF to non-exposed rats significantly decreased triglyceride serum levels and failed to influence other metabolic parameters (Figure 1). Dramatic parameter disturbances were observed in DMH and water-treated rats. The animals were sacrificed six months after the first carcinogen injection. Compared withthe control group, non-treated rats had increased levels of glucose (+25.6%), insulin (+36.2%), IGF-1 (+37.1%), total cholesterol (+47.4%), and triglycerides (+106.9%) and increased activities of catalase (+35.3%), MDA (+33.3%), AST (+93.8%), ALT (+71.4%), VEGF (+65.5%), and glycated hemoglobin (+56.7%). SOD activity did not change significantly (+19.2%, P>0.05). Both MF doses alleviated carcinogenic effects. Majority of parameters were normal, and indices covered those DMH-unexposed and MF-untreated rats (Figure 1A–1M).

    Figure 1 Effect of 1,2-dimethylhydrazine (DMH) and metformin on hormonal and metabolic parameters in the serum male Wistar rats. (A) glucose. (B) Insulin. (C) IGF-1. (D) Total cholesterol. (E) Triglycerides. (F) Cu, Zn-superoxide dismutase. (G) Catalase. (H) Malonic dialdehyde. (I) Hemoglobin. (J) Glycated hemoglobin. (K) Alaninaminetransferase. (L) Aspartataminetransferase. (M) VEGF. Data presented as mean±SEM, n=6–15 per group. P≤0.05. a: DMH vs. control; b: DMH+MF vs. DMH. Rats bearing DMH-induced colon adenocarcinomas have elevated serum level of glucose, insulin, IGF-1, total cholesterol, triglycerides, catalase, malonic dialdehyde, glycated hemoglobin, AST, ALT and decreased level of hemoglobin. Treatment with MF in both doses normalized majority of these changes in DMH-treated group of rats, whereas failed to modify them in rats not treated with DMH. Only exception was decreased level of triglycerides in MF-treated rats (Figure 1E, P<0.05).

    Table 1 Colon tumors localization, incidence, multiplicity and size in rats exposed to 1,2-dimethylhydrazine (DMH) and metformin

    Effects of MF on DMH-induced colon carcinogenesis in male rats

    In Experiment 2, intestinal tumors were found in majority of DMH-exposed rats (Table 1).

    In group 1 (DMH+water), all rats developed colon tumors (100%). Tumor incidences in different colon parts in group 1 varied: 63% in ascending colon, 100% in descending colon, and 25% in rectum. Moreover, 76.7% of colon tumors were observed in descending colons, 16.7% in ascending colons, and 6.7% in rectums. Maximal effect of 100 mg/kg daily MF dose was observed in the ascending colon, in which DMH-induced carcinogenesis was also completely inhibited (Table 1). The two MF doses did not affect colon carcinoma incidence in rat rectums and descending colons. Higher MF dose (300 mg/kg) was less effective in suppressing colon carcinogenesis compared with lower amounts (100 mg/kg).

    Macroscopically, neoplasms are exophytic or endophytic. Microscopically, malignant intestinal tumors have different types, among which tubular adenocarcinomas are predominant. All carcinoma types are typical in DMH-induced neoplasms15. Table 1 and Figure 2 present the data on the effects of MF on DMH-induced colon tumor development.

    Figure 2 Effect of metformin on some parameters of 1,2-dimethylhydrazine-induced colon carcinogenesis in male Wistar rats. Data presented as mean±SEM, n=7–9 per group. * Р<0.01; § P<0.05 vs. DMH group. Treatment with MF in dose 100 mg/kg increased relative number of induced with DMH exophytic colon carcinomas and decreased number of endophytic tumors. Both doses of MF increased relative number of DMH-induced highly differentiated tumors and decreased invasiveness of colon carcinomas as compare with group given DMH with water.

    Morphological analysis showed that tumors with exophytic growth patterns developed more frequently in the group treated with 100 mg/kg MF compared with DMH + water group. Opposite results were observed with endophytic colon tumors (Figure 2A). The group that was treated with lower MF dose had less invasive (Figure 2B) and more differentiated tumors (Figure 2C) compared with the DMH + water group. Figure 3 shows microphotographs of the observed colon adenocarcinoma types. Tumor size distribution analysis showed that in descending colons of DMH + water and DMH + MF groups, 300 small tumors (<10 mm2) appeared less frequently compared with the MF group with 100 mg/kg dose (26%, 26%, and 50%, correspondingly). Thus, these data indicate the inhibitory effects of MF on DMH-induced colon carcinogenesis.

    Discussion

    The DMH-induced carcinogenesis in epithelial cells includes the following: formation of most active metabolites (methylazoxymethanol or methyldiazohydrate) in the liver; binding of metabolites to glucuronic acid; delivery of conjugates to intestines via blood flow; release of active metabolites through enzymatic activity of intestinal flora (?glucuronidase); formation of carbonium ion (CH3+); specific methylation of macromolecules, which in enterocytes, are mainly DNA at O6position of guanine; miscoding effects7. These events result in mutation and activation of Ki-ras oncogene and inactivation of p5317. Moreover, reports presented the significant role of free radicals in DMH-induced colon carcinogenesis18,19. The present study confirmed the effects of DMH on oxidative stress parameters. Furthermore, we showed the normalizing effect of MF on MDA levels in DMH-treated rats (Figure 1). Bordini et al.20observed similar effects of MF in azoxymethane (AOM)-exposed mice. Shortly after starting DMH treatment, exposed organisms experienced significant disturbances in their neuroendocrine and immune systems and lipid and carbohydrate metabolisms. DMH treatment was followed by an increase in sensitivity threshold of the hypothalamus to inhibition by estrogen21, decrease in hypothalamic biogenic amine content22, and disturbances in diurnal rhythms at biogenic amine levels in hypothalamic nuclei of rats23. Antidiabetic biguanide treatment alleviated immunodepression in rodents exposed to DMH24and AOM25. We observed increased levels of glucose, insulin, IGF-1, total cholesterol, triglycerides, MDA, glycated hemoglobin, and VEGF in serum of rats with DMH-induced colon tumors compared with the group without DMH (Figure 1). These findingsagree with available data12,13,26,27. Furthermore, we observed the normalizing effects of both MF doses on these parameters in DMH-exposed rats (Figure 1). Notably, AST and ALT levels were not different in rats treated with higher and lower MF doses, thereby suggesting the non-toxicity of MF on liver functions.

    Figure 3 Microphotographs of 1,2-dimethylhydrazine-induced colon adenocarcinomas. (A) Highly differentiated adenocarcinoma. (B) Moderately differentiated adenocarcinoma. (C) Low differentiated adenocarcinoma (H&E stainning, 70×).

    Table 2 summarizes the data on inhibitory effects of antidiabetic biguanides on colon carcinogenesis. In most studies, anti-diabetic biguanides inhibited AOM- or DMH-induced colon carcinogenesis in mice and rats. Detailed analysis of experimental results are provided elsewhere28,29. MF treatment was followed by decreased levels of proliferation indices, which were evaluated with 5-bromodesoxyuridine, proliferating cell nuclear antigen indices, phosphorylated mechanistic target of rapamycin (mTOR), S6 kinase, and S6 proteins, as revealed by Western blot analysis, in the colonic mucosa of AOM-treated mice30. The authors believe that MF suppresses colonic epithelial proliferation by inhibiting the mTOR pathway through 5’ adenosine monophosphateactivated protein kinase activation. However, MF did not affect the level of O6-Methylguanin in the colon or liver of AOM-treated mice. Results showed that MF did not affect the AOM alkylation capacity and carcinogenicity. Therefore, the normalizing effect of MF on neuroendocrine and hormonal metabolic shifts, which occurred in rodents during colon carcinogenesis, are critical in colon cancer prevention.

    Zaafar et al.32studied the effects of MF on cancer development in diabetic and non- diabetic mice. In diabetic mice, MF treatment alone increased the number of surviving mice compared with the diabetic DMH group. Moreover, MF significantly reduced histopathological scores in diabetic mice colons. Serum VEGF levels in non-diabetic DMH group were not significantly higher than those of non-diabetic saline groups. In non-diabetic mice, MF reduced the serum concentration of VEGF compared with those in the nondiabetic/DMH control. In our study, we observed a tendency toward an increased VEGF level in DMH-treated rats compared with control animals, which were not exposed to carcinogens, whereas MF did not influence this parameter. Statistical analysis showed a significantly reduced histopathologic score for colon mucosa of MF-treated diabetic mice compared with DMH control, whereas in nondiabetic animals, the drug failed to improve the scores. This study highlighted the high susceptibility of diabetic rodents to carcinogenic effects of DMH. Inhibitory effects of MF on DMH-induced colon carcinogenesis were observed in Sprague Dawley rats with type 2 diabetes; the condition was induced with small dose of streptozotocin combined with a high-fat diet12. MF treatment was followed by decreases in ACF number, colonic tissue proliferation, and colon tumor incidence, multiplicity, and size. These results and other studies confirmed the role of diabetes as risk factor for cancer and established a connection between glucose levels and development of micro- and macro-vascular complications37,38. Our data agree with the other studies, showing that MF is effective in cancer prevention in both diabetic and non-diabetic animals that are exposed to DMH or AOM (Table 2)10,11. Moreover, clinical trials demonstrated the decrease in colon cancer risk of type 2 diabetes and non-diabetic patients39-51. Meta-analysis of 37 studiescomprising more than 1.5 million participants showed that risk of colon cancer mortality was reduced by 23% in MF users compared with non-users46. Thus, most epidemiological data and clinical trial results present sufficient evidence of MF efficacy in CRC prevention and treatment in humans. Furthermore, low daily MF dose (500 mg) was effective in reducing cancer risk in type 2 diabetes patients52. Our findings on efficacy of lower MF dose in rats agree with clinical data. Given the practical significance of these observations, future investigations are needed to elucidate the advantage of using lower doses of the drug.

    Table 2 Effect of anti-diabetic drugs on colon carcinogenesis in rodents

    Acknowledgments

    This work was supported in part by a grant from the Russian Foundation for Basic Research (Grant No. 14-04-01653). Authors are very thankful to Dr. A.V. Panchenko and Dr. M.A. Zabezhinski for help and valuable advice during the study.

    Conflict of interest statement

    No potential conflicts of interest are disclosed.

    1.Globocan 2013, Cancer Fact Sheets for Colorectal Cancer. http://globocan.iarc.fr/old/FactSheets/cancers/colorectal-new.asp.

    2.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10–29.

    3.Dilman VM. Development, Aging and Disease: A New Rationale for an Intervention. Chur: Harwood Academic Publishers; 1994.

    4.Facchini F, Hua N, Abbasi F, Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001; 86: 3574–8.

    5.Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002; 11: 385–91.

    6.Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer. 2010; 17: 351–60.

    7.Pozharisski KM, Likhachev AJ, Klimashevski VF, Shaposhnikov JD. Experimental intestinal cancer research with special reference to human pathology. Adv Cancer Res. 1979; 30: 165–237.

    8.Rogers AE, Nauss KM. Rodent models for carcinoma of the colon. Dig Dis Sci. 1985; 30: 87S-102S.

    9.Shaw RJ, Lamia KA, Vasques D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005; 310: 1642–6.

    10.Anisimov VN. Metformin for cancer and aging prevention: is it a time to make the long story short? Oncotarget. 2015; 6: 39398–407.

    11.Anisimov VN. Metformin for prevention and treatment of colon cancer: a reappraisal of experimental and clinical data. Current Drug Target. 2016; 17: 439–46.

    12.Jia YL, Ma ZY, Liu XF, Zhou WJ, He S, Xu X, et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the Warburg effect. Cancer Med. 2015; 4: 1730–41.

    13.Li W, Wang QL, Liu X, Dong SH, Li HX, Li CY, et al. Combined use of vitamin D3 and metformin exhibits synergistic chemopreventive effects on colorectal neoplasia in rats and mice. Cancer Prev Res. 2015; 8: 139–48.

    14.Anisimov VN, Popovich IG, Zabezhinski MA. Methods of testing pharmacological drugs effects on aging and life span in mice. In: Tollefsbol TO, editor. Biological Aging: Methods and Protocols. 2nd ed. New York: Humana Press; 2013. p.145–60.

    15.Turusov VS. Pathology of Tumours in Laboratory Animals, Vol. 1: Tumours of the Rat. 2nd ed. Lyon: International Agency for Research on Cancer; 1990.

    16.Goubler EV. Calculation Methods in Analysis and Identification of Pathological Processes. Moscow: Meditsina; 1978.

    17.Zusman I. The role of p53 tumor-associated protein in colon cancer detection and prevention (Review). Int J Oncol. 1997; 10: 1241–9.

    18.Salim AS. The permissive role of oxygen-derived free radicals in the development of colonic cancer in the rat. A new theory for carcinogenesis. Int J Cancer. 1993; 53: 1031–5.

    19.Arutiunian AV, Prokopenko VM, Burmistrov SO, Oparina TI, Frolova EV, Zabezhinsk? MA, et al. Free-radical processes in blood serum, liver and large bowel during 1,2-dimethylhydrazine-induced carcinogenesis in rats. Vopr Onkol. 1997; 43: 618–22.

    20.Bordini HP, Kremer JL, Fagundes TR, Melo GP, Conchon-Costa I, da Silva SS, et al. Protective effect of metformin in an aberrant crypt foci model induced by 1, 2-dimethylhydrazine: Modulation of oxidative stress and inflammatory process. Mol Carcinog. 2016. DOI: 10.1002/mc.22545.

    21.Pozharisski K, Anisimov V. On the role of endocrine system in development of experimental colon tumors in rats. Pathol Physiol. 1975; 1: 47–50.

    22.Anisimov VN, Pozdeev VK, Dmitrievskaia A, Gracheva GM, Il’in AP. Effect of enterotropic carcinogen 1, 2-dimethylhydrazine on the level of biogenic amines in the hypothalamus of rats. Bull Eksp Biol Med. 1976; 82: 1359–61.

    23.Arutjunyan AV, Kerkeshko GO, Anisimov VN, Stepanov MG, Prokopenko VM, Pozdeyev NV, et al. Disturbances of diurnal rhythms of biogenic amines contents in hypothalamic nuclei as an evidence of neurotropic effects of enterotropic carcinogen 1, 2-dimethylhydrazine. Neuro Endocrinol Lett. 2001; 22: 229–37.

    24.Dil’man VM, Sofronov BN, Anisimov VN, Nazarov PG, L’vovich EG. Phenformin elimination of the immunodepression caused by 1, 2-dimethylhydrazine in rats. Vopr Onkol. 1977; 23: 50–4.

    25.Chung EJ, Do EJ, Kim SY, Cho EA, Kim DH, Pak S, et al. Combination of metformin and VSL#3 additively suppresses western-style diet induced colon cancer in mice. Eur J Pharmacol.2017; 794: 1–7.

    26.Dubina MV, Petrishchev NN, Anisimov VN. Microvascular endothelium dysfunction in rats bearing 1, 2-dimethylhydrazineinduced colon tumors. Cancer Lett. 1999; 144: 125–9.

    27.Shimomoto T, Luo Y, Ohmori H, Chihara Y, Fujii K, Sasahira T, et al. Advanced glycation end products (AGE) induce the receptor for AGE in the colonic mucosa of azoxymethane-injected Fischer 344 rats fed with a high-linoleic acid and high-glucose diet. J Gastroenterol. 2012; 47: 1073–83.

    28.Anisimov VN. Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Trans Med. 2014; 2: 60.

    29.Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY). 2010; 2: 760-74.

    30.Hosono K, Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49: 662–71.

    31.Abdulkareem HA, Hussein AG, Mahmood AS. Efficacy of intraperitoneal administration of metformin and 5-fluoruracil in prevention of induced-colorectal aberrant crypt foci in mice. Int J Pharmacy Pharmaceut Sci. 2014; 6: 305–8.

    32.Zaafar DK, Zaitone SA, Moustafa YM. Role of metformin in suppressing 1, 2-dimethylhydrazine-induced colon cancer in diabetic and non-diabetic mice: effect on tumor angiogenesis and cell proliferation: PLoS One. 2014; 9: e100562.

    33.Rao CV, Janakiram NB, Mohammed A, Madka V, Qian L, Brewer M, et al. Lack of chemopreventive effects of metformin in azoxymethane-induced rat colon carcinogenesis. Cancer Prev Res. 2011; 4: B42.

    34.Madka V, Zhang Y, Brewer M, Rao C, Janakiram N, Mohammed A, et al. Chemopreventive efficacy of bisphosphonates, Zometa and Fosamax, alone or in combination with metformin in AOM-induced rat colon cancer model. Cancer Prev Res. 2013; 6: A14.

    35.Anisimov VN, Pozharisski? KM, Dil’man VM. Effect of phenformin on the blastomogenic action of 1, 2-dimethylhydrazine in rats. Vopr Onkol. 1980; 26: 54–8.

    36.Popovich IG, Zabezhinski MA, Egormin PA, Tyndyk ML, Anikin IV, Spasov AA, et al. Insulin in aging and cancer: antidiabetic drug diabenol as geroprotector and anticarcinogen. Int J Biochem Cell Biol. 2005; 37: 1117–29.

    37.Markowitz SD, Bertagnolli MM. Molecular basis for colorectal cancer. N Engl J Med. 2009; 361: 2449–60.

    38.Feng YH, Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, et al. microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cells. Int J Mol Med. 2012; 29: 920–6.

    39.Zhang PP, Li H, Tan XH, Chen LL, Wang SM. Association of metformin use with cancer incidence and mortality: A metaanalysis. Cancer Epidemiol. 2013; 37: 207–18.

    40.Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res. 2010; 3: 1077–83.

    41.Higurashi T, Takahashi H, Endo H, Hosono K, Yamada E, Ohkubo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012; 12: 118.

    42.Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, et al. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS One. 2014; 9: e91818.

    43.Cardel M, Jensen SM, Potteg?rd A, J?rgensen TL, Hallas J. Longterm use of metformin and colorectal cancer risk in type II diabetics: a population-based case-control study. Cancer Med. 2014; 3: 1458–66.

    44.Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29: 1314–27.

    45.Nangia-Makker P, Yu YJ, Vasudevan A, Farhana L, Rajendra SG, Levi E, et al. Metformin: a potential therapeutic agent for recurrent colon cancer. PLoS One. 2014; 9: e84369.

    46.Zhang YF, Guan MP, Zheng ZJ, Zhang Q, Gao F, Xue YM. Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. PLoS One. 2013; 8: e81264.

    47.Zhang ZJ, Zheng ZJ, Kan HD, Song YQ, Cui W, Zhao GM, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34: 2323–8.

    48.Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766–77.

    49.Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: A systematic review and meta-analysis. Oncologist. 2013; 18: 1248–55.

    50.Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2013; 22: 1877–83.

    51.Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E, et al. Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016; 17: 475–83.

    52.Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang HY, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800, 000 individuals. BMC Cancer. 2011, 11: 20.

    Cite this article as:Bekusova VV, Patsanovskii VM, Nozdrachev AD, Trashkov AP, Artemenko MR, Anisimov VN, et al. Metformin prevents hormonal and metabolic disturbances and 1,2-dimethylhydrazine-induced colon carcinogenesis in non-diabetic rats. Cancer Biol Med. 2017; 14: 100-7. doi: 10.20892/j.issn.2095-3941.2016.0088

    Viktoria V. Bekusova

    E-mail: v.bekusova@spbu.ru

    Received October 26, 2016; accepted November 28, 2016. Available at www.cancerbiomed.org

    Copyright ? 2017 by Cancer Biology & Medicine

    日本欧美国产在线视频| 夫妻午夜视频| 国产探花极品一区二区| 国产精品麻豆人妻色哟哟久久| 国产一级毛片在线| 我要看黄色一级片免费的| 国产av国产精品国产| 中文字幕最新亚洲高清| 亚洲精品乱久久久久久| av在线观看视频网站免费| 永久免费av网站大全| 久久精品国产亚洲av高清一级| 人人妻人人澡人人爽人人夜夜| 99re6热这里在线精品视频| 国产午夜精品一二区理论片| 考比视频在线观看| 免费少妇av软件| 乱人伦中国视频| 日韩一区二区三区影片| 9热在线视频观看99| av女优亚洲男人天堂| 亚洲国产色片| 一二三四在线观看免费中文在| 国产精品久久久久久精品电影小说| 国产免费视频播放在线视频| 黑人欧美特级aaaaaa片| 黄片播放在线免费| 日韩av免费高清视频| 自拍欧美九色日韩亚洲蝌蚪91| 国产成人91sexporn| 亚洲国产av新网站| 精品久久久久久电影网| 搡女人真爽免费视频火全软件| 亚洲精品,欧美精品| 在线观看免费日韩欧美大片| 精品福利永久在线观看| 精品福利永久在线观看| 肉色欧美久久久久久久蜜桃| 丝袜美腿诱惑在线| 中文字幕另类日韩欧美亚洲嫩草| 久久人妻熟女aⅴ| 欧美xxⅹ黑人| 亚洲欧美精品自产自拍| 边亲边吃奶的免费视频| 高清黄色对白视频在线免费看| 久久人妻熟女aⅴ| 制服丝袜香蕉在线| 永久网站在线| 精品福利永久在线观看| 日韩人妻精品一区2区三区| 在线看a的网站| 精品人妻偷拍中文字幕| 老鸭窝网址在线观看| 老鸭窝网址在线观看| 超色免费av| 日本av免费视频播放| 制服诱惑二区| 久久久久精品久久久久真实原创| 久久精品国产自在天天线| 日本色播在线视频| 久久久久精品久久久久真实原创| 一本—道久久a久久精品蜜桃钙片| 777米奇影视久久| 日日撸夜夜添| 日韩中文字幕视频在线看片| 欧美国产精品一级二级三级| 多毛熟女@视频| 亚洲欧洲精品一区二区精品久久久 | 看免费av毛片| 亚洲,一卡二卡三卡| 王馨瑶露胸无遮挡在线观看| 欧美国产精品va在线观看不卡| 女性被躁到高潮视频| 欧美 亚洲 国产 日韩一| 一二三四在线观看免费中文在| 另类精品久久| 精品人妻一区二区三区麻豆| 国产精品女同一区二区软件| 国产男女内射视频| 亚洲精品久久午夜乱码| www日本在线高清视频| 飞空精品影院首页| 久久久国产欧美日韩av| 久久婷婷青草| 18禁动态无遮挡网站| 日韩成人av中文字幕在线观看| 狠狠婷婷综合久久久久久88av| 午夜免费鲁丝| 亚洲色图 男人天堂 中文字幕| 免费观看av网站的网址| 亚洲欧美日韩另类电影网站| 夫妻午夜视频| a级毛片在线看网站| 日韩视频在线欧美| 韩国精品一区二区三区| 亚洲图色成人| 国产色婷婷99| 日韩一区二区视频免费看| 久久亚洲国产成人精品v| 老汉色av国产亚洲站长工具| 亚洲精品一二三| 亚洲男人天堂网一区| 国产成人精品在线电影| 欧美日韩一区二区视频在线观看视频在线| 99国产综合亚洲精品| 日韩av在线免费看完整版不卡| 91午夜精品亚洲一区二区三区| 亚洲精品自拍成人| 91国产中文字幕| 大香蕉久久成人网| 中文欧美无线码| 少妇人妻久久综合中文| 极品人妻少妇av视频| 七月丁香在线播放| 亚洲一级一片aⅴ在线观看| 日本猛色少妇xxxxx猛交久久| 欧美中文综合在线视频| 搡老乐熟女国产| 天美传媒精品一区二区| 亚洲色图综合在线观看| videossex国产| 久久国内精品自在自线图片| 欧美精品亚洲一区二区| 性色av一级| 亚洲少妇的诱惑av| 午夜福利乱码中文字幕| 精品少妇黑人巨大在线播放| 成人亚洲精品一区在线观看| 欧美日韩一区二区视频在线观看视频在线| 纵有疾风起免费观看全集完整版| 18在线观看网站| av福利片在线| 日韩大片免费观看网站| 欧美精品av麻豆av| 亚洲精品av麻豆狂野| videossex国产| 老司机影院成人| 另类精品久久| 久久久久精品性色| 桃花免费在线播放| 国产亚洲欧美精品永久| 激情五月婷婷亚洲| 黄色怎么调成土黄色| 9191精品国产免费久久| 亚洲av免费高清在线观看| 日韩一区二区三区影片| 日韩制服丝袜自拍偷拍| 精品国产一区二区三区四区第35| 中文字幕人妻丝袜一区二区 | 成年人免费黄色播放视频| 99精国产麻豆久久婷婷| 边亲边吃奶的免费视频| av免费观看日本| 欧美日韩亚洲国产一区二区在线观看 | 中文字幕另类日韩欧美亚洲嫩草| 青草久久国产| 一边亲一边摸免费视频| 卡戴珊不雅视频在线播放| 人妻少妇偷人精品九色| 黑人巨大精品欧美一区二区蜜桃| 80岁老熟妇乱子伦牲交| 久久女婷五月综合色啪小说| 国产女主播在线喷水免费视频网站| 亚洲激情五月婷婷啪啪| 极品人妻少妇av视频| 欧美精品av麻豆av| 人妻人人澡人人爽人人| 亚洲三区欧美一区| 涩涩av久久男人的天堂| 亚洲第一青青草原| 免费高清在线观看日韩| 一级毛片 在线播放| 国产日韩一区二区三区精品不卡| 亚洲av免费高清在线观看| 纯流量卡能插随身wifi吗| 久久毛片免费看一区二区三区| 国产精品av久久久久免费| 欧美日韩视频精品一区| 有码 亚洲区| av国产久精品久网站免费入址| 性色av一级| 国产免费又黄又爽又色| 成人免费观看视频高清| 2022亚洲国产成人精品| 色婷婷av一区二区三区视频| 搡老乐熟女国产| 一二三四在线观看免费中文在| 亚洲美女搞黄在线观看| 国产淫语在线视频| 五月开心婷婷网| 两性夫妻黄色片| 又粗又硬又长又爽又黄的视频| 看免费av毛片| 欧美精品亚洲一区二区| 精品亚洲成国产av| 伦理电影大哥的女人| 国产精品偷伦视频观看了| 一本—道久久a久久精品蜜桃钙片| 亚洲 欧美一区二区三区| 最近的中文字幕免费完整| 国产精品麻豆人妻色哟哟久久| 美女高潮到喷水免费观看| 欧美亚洲 丝袜 人妻 在线| 大码成人一级视频| 王馨瑶露胸无遮挡在线观看| 国产欧美日韩一区二区三区在线| 赤兔流量卡办理| 大话2 男鬼变身卡| 免费播放大片免费观看视频在线观看| av一本久久久久| 春色校园在线视频观看| 如何舔出高潮| 少妇的逼水好多| 亚洲欧美一区二区三区黑人 | 亚洲国产精品成人久久小说| 久久久久久人妻| 熟女av电影| 天天躁夜夜躁狠狠久久av| 国产麻豆69| xxxhd国产人妻xxx| 麻豆精品久久久久久蜜桃| 国产xxxxx性猛交| 色94色欧美一区二区| 国产精品偷伦视频观看了| 国产男人的电影天堂91| 亚洲国产欧美网| 欧美亚洲日本最大视频资源| 久久久精品免费免费高清| 成年美女黄网站色视频大全免费| 亚洲色图 男人天堂 中文字幕| 欧美国产精品一级二级三级| 国产精品熟女久久久久浪| 97在线人人人人妻| 黄色配什么色好看| 亚洲精品,欧美精品| www.精华液| 午夜福利影视在线免费观看| 久久久久久久国产电影| 国产精品国产av在线观看| 母亲3免费完整高清在线观看 | 我的亚洲天堂| 天堂俺去俺来也www色官网| 亚洲视频免费观看视频| 一级,二级,三级黄色视频| 一本色道久久久久久精品综合| av卡一久久| 晚上一个人看的免费电影| kizo精华| freevideosex欧美| 国产激情久久老熟女| 春色校园在线视频观看| 国产在线一区二区三区精| 日韩熟女老妇一区二区性免费视频| 日本午夜av视频| 国产精品女同一区二区软件| 人妻系列 视频| 午夜免费男女啪啪视频观看| 伊人亚洲综合成人网| 欧美中文综合在线视频| av女优亚洲男人天堂| 一级爰片在线观看| 一级毛片黄色毛片免费观看视频| 成人国语在线视频| av电影中文网址| 精品亚洲乱码少妇综合久久| 捣出白浆h1v1| 看非洲黑人一级黄片| 国产av国产精品国产| 啦啦啦啦在线视频资源| 久久毛片免费看一区二区三区| 日韩av在线免费看完整版不卡| 多毛熟女@视频| 97人妻天天添夜夜摸| 欧美在线黄色| 你懂的网址亚洲精品在线观看| 一级毛片 在线播放| 性色avwww在线观看| 亚洲伊人色综图| 国产成人精品在线电影| 国产成人91sexporn| 大片免费播放器 马上看| 老熟女久久久| 免费大片黄手机在线观看| 亚洲天堂av无毛| 91精品国产国语对白视频| 久久久久久久国产电影| 性高湖久久久久久久久免费观看| 免费观看a级毛片全部| 亚洲 欧美一区二区三区| 在线亚洲精品国产二区图片欧美| 十八禁网站网址无遮挡| 午夜av观看不卡| 亚洲色图综合在线观看| 九九爱精品视频在线观看| 一级毛片黄色毛片免费观看视频| videosex国产| 一区二区av电影网| 2021少妇久久久久久久久久久| h视频一区二区三区| 人成视频在线观看免费观看| av一本久久久久| 久久久久久免费高清国产稀缺| 国产一区二区激情短视频 | 久久青草综合色| 热99久久久久精品小说推荐| 亚洲欧洲日产国产| 久久婷婷青草| 一级片'在线观看视频| 新久久久久国产一级毛片| 日本色播在线视频| 亚洲av综合色区一区| 男女下面插进去视频免费观看| 久久韩国三级中文字幕| 国产av一区二区精品久久| 亚洲一级一片aⅴ在线观看| 久久人人97超碰香蕉20202| 青草久久国产| 国产亚洲一区二区精品| freevideosex欧美| 亚洲精品第二区| 精品福利永久在线观看| 中文乱码字字幕精品一区二区三区| 99精国产麻豆久久婷婷| 日韩欧美精品免费久久| 叶爱在线成人免费视频播放| 成人漫画全彩无遮挡| 高清在线视频一区二区三区| 美女高潮到喷水免费观看| 99久久人妻综合| 国产一区二区三区综合在线观看| 日韩av免费高清视频| 十八禁高潮呻吟视频| 亚洲精品,欧美精品| 欧美日韩av久久| 成人亚洲欧美一区二区av| 久久久久久久久免费视频了| 欧美精品高潮呻吟av久久| 美女主播在线视频| 欧美日韩av久久| 美女脱内裤让男人舔精品视频| 欧美日韩视频高清一区二区三区二| 男人添女人高潮全过程视频| 亚洲天堂av无毛| 免费黄色在线免费观看| 亚洲欧美精品自产自拍| 卡戴珊不雅视频在线播放| kizo精华| 一级片'在线观看视频| 新久久久久国产一级毛片| 中文字幕人妻熟女乱码| 97人妻天天添夜夜摸| 伦精品一区二区三区| 中文字幕色久视频| 婷婷色av中文字幕| 国产精品 国内视频| 一本久久精品| 美女高潮到喷水免费观看| xxx大片免费视频| 在线亚洲精品国产二区图片欧美| 亚洲一区二区三区欧美精品| 欧美人与性动交α欧美软件| 免费大片黄手机在线观看| 中文精品一卡2卡3卡4更新| 18禁动态无遮挡网站| 1024视频免费在线观看| 精品少妇内射三级| 亚洲欧美成人精品一区二区| 99久久中文字幕三级久久日本| 国产一级毛片在线| 亚洲精品日韩在线中文字幕| 在现免费观看毛片| 波野结衣二区三区在线| 丰满迷人的少妇在线观看| 国产日韩欧美在线精品| 26uuu在线亚洲综合色| 女性被躁到高潮视频| 黄色一级大片看看| av网站在线播放免费| 少妇 在线观看| 欧美激情极品国产一区二区三区| 国产男女内射视频| 国产精品蜜桃在线观看| 国产成人精品久久二区二区91 | 寂寞人妻少妇视频99o| 国产高清国产精品国产三级| 欧美变态另类bdsm刘玥| 丰满迷人的少妇在线观看| 久久av网站| 久久久久人妻精品一区果冻| 国产毛片在线视频| av国产精品久久久久影院| 在线天堂中文资源库| 少妇猛男粗大的猛烈进出视频| 国产一区二区三区综合在线观看| 嫩草影院入口| 免费女性裸体啪啪无遮挡网站| 亚洲av免费高清在线观看| 久久99一区二区三区| 久久久久精品性色| 国产极品天堂在线| 欧美 日韩 精品 国产| 国产熟女午夜一区二区三区| 老熟女久久久| 成年女人毛片免费观看观看9 | 中文字幕精品免费在线观看视频| 国产免费福利视频在线观看| 9热在线视频观看99| 男女边摸边吃奶| 黄网站色视频无遮挡免费观看| 一区二区三区精品91| 天堂俺去俺来也www色官网| 成人黄色视频免费在线看| 黄色 视频免费看| 五月伊人婷婷丁香| 伊人久久国产一区二区| 777米奇影视久久| 美女中出高潮动态图| 黑人猛操日本美女一级片| 熟女av电影| 亚洲精品久久午夜乱码| 免费高清在线观看日韩| 老司机影院成人| 母亲3免费完整高清在线观看 | 久久精品国产亚洲av高清一级| 老司机影院成人| 日韩av不卡免费在线播放| 少妇熟女欧美另类| 美女主播在线视频| 久久精品夜色国产| 天堂中文最新版在线下载| 久久热在线av| 视频区图区小说| 国产一级毛片在线| 亚洲一区二区三区欧美精品| 国产精品熟女久久久久浪| 国产av精品麻豆| 中国国产av一级| 国产不卡av网站在线观看| xxx大片免费视频| 国产一级毛片在线| 在线看a的网站| 精品卡一卡二卡四卡免费| 80岁老熟妇乱子伦牲交| 中文字幕人妻熟女乱码| 麻豆精品久久久久久蜜桃| 美女大奶头黄色视频| 免费观看无遮挡的男女| 欧美+日韩+精品| 欧美日韩亚洲国产一区二区在线观看 | 欧美bdsm另类| 亚洲精品中文字幕在线视频| 亚洲激情五月婷婷啪啪| 亚洲国产色片| 国产免费福利视频在线观看| 国产精品无大码| 18禁国产床啪视频网站| 国产在线免费精品| 一二三四中文在线观看免费高清| www.av在线官网国产| 一区在线观看完整版| 下体分泌物呈黄色| 亚洲激情五月婷婷啪啪| 制服人妻中文乱码| 久久久精品免费免费高清| 在线观看三级黄色| 巨乳人妻的诱惑在线观看| √禁漫天堂资源中文www| 亚洲成av片中文字幕在线观看 | 午夜精品国产一区二区电影| 少妇的丰满在线观看| 午夜福利一区二区在线看| 黑人欧美特级aaaaaa片| 国产高清不卡午夜福利| 亚洲国产精品成人久久小说| 如日韩欧美国产精品一区二区三区| 久久精品国产亚洲av天美| 日韩三级伦理在线观看| 黄片小视频在线播放| 午夜福利视频精品| 久久精品国产亚洲av高清一级| 日韩一区二区三区影片| 亚洲国产av新网站| 久热这里只有精品99| 午夜免费鲁丝| 日本免费在线观看一区| 麻豆精品久久久久久蜜桃| 亚洲美女视频黄频| 欧美av亚洲av综合av国产av | 久久久久国产精品人妻一区二区| 欧美亚洲 丝袜 人妻 在线| 熟妇人妻不卡中文字幕| 欧美日韩亚洲国产一区二区在线观看 | 国产精品一区二区在线不卡| 色94色欧美一区二区| 亚洲国产色片| 欧美人与性动交α欧美精品济南到 | 欧美日本中文国产一区发布| 午夜老司机福利剧场| 日韩av不卡免费在线播放| 欧美日韩亚洲高清精品| 中文精品一卡2卡3卡4更新| 国产成人一区二区在线| 美国免费a级毛片| 亚洲一区二区三区欧美精品| 韩国精品一区二区三区| 多毛熟女@视频| 免费大片黄手机在线观看| 99久国产av精品国产电影| 这个男人来自地球电影免费观看 | 女性生殖器流出的白浆| 国产精品久久久久久精品电影小说| 久久99蜜桃精品久久| 欧美 日韩 精品 国产| 少妇被粗大猛烈的视频| 国产欧美日韩一区二区三区在线| 久久国产精品男人的天堂亚洲| 成人国产麻豆网| 黑人巨大精品欧美一区二区蜜桃| 中文字幕人妻熟女乱码| 午夜精品国产一区二区电影| 亚洲精品久久久久久婷婷小说| 建设人人有责人人尽责人人享有的| 大香蕉久久成人网| 秋霞在线观看毛片| a级毛片在线看网站| 最近2019中文字幕mv第一页| 大话2 男鬼变身卡| 美国免费a级毛片| 亚洲成人av在线免费| 日日爽夜夜爽网站| a级片在线免费高清观看视频| 熟女少妇亚洲综合色aaa.| 欧美在线黄色| 亚洲av福利一区| 亚洲三级黄色毛片| 国产男女内射视频| 考比视频在线观看| 久久影院123| 亚洲男人天堂网一区| 亚洲精品av麻豆狂野| 永久免费av网站大全| 老汉色∧v一级毛片| 亚洲国产欧美在线一区| 91精品三级在线观看| 老司机亚洲免费影院| 亚洲天堂av无毛| 美女午夜性视频免费| 看免费av毛片| 成人毛片a级毛片在线播放| 999久久久国产精品视频| 夫妻午夜视频| 久久国产精品大桥未久av| 国产日韩欧美视频二区| 成人国语在线视频| 不卡视频在线观看欧美| 国产精品嫩草影院av在线观看| 婷婷色综合大香蕉| 秋霞伦理黄片| 精品国产国语对白av| 免费高清在线观看视频在线观看| 午夜福利视频在线观看免费| 丰满迷人的少妇在线观看| 肉色欧美久久久久久久蜜桃| 国产一级毛片在线| 色哟哟·www| 亚洲av电影在线进入| 亚洲三区欧美一区| 精品久久蜜臀av无| 老汉色av国产亚洲站长工具| 亚洲欧美中文字幕日韩二区| 国产麻豆69| 亚洲第一青青草原| 亚洲四区av| 少妇被粗大猛烈的视频| 少妇被粗大的猛进出69影院| 9191精品国产免费久久| 中文欧美无线码| 欧美在线黄色| 男男h啪啪无遮挡| 日产精品乱码卡一卡2卡三| 丁香六月天网| 久久99热这里只频精品6学生| 中文天堂在线官网| 精品亚洲乱码少妇综合久久| 黄片播放在线免费| 国产成人精品无人区| 久久久久久久国产电影| 成人影院久久| 精品国产乱码久久久久久男人| 久热久热在线精品观看| 国产男女内射视频| 久久久久久久久久人人人人人人| 热re99久久精品国产66热6| 午夜激情久久久久久久| 女人久久www免费人成看片| 一边摸一边做爽爽视频免费| 成年女人毛片免费观看观看9 | 日韩欧美精品免费久久| 国产精品无大码| 成年女人在线观看亚洲视频| 午夜日韩欧美国产| 欧美精品一区二区免费开放| 成年女人在线观看亚洲视频| videossex国产| 国产一区二区三区av在线| 成年动漫av网址| 精品国产国语对白av| 欧美日韩视频精品一区| 精品人妻在线不人妻| 天天躁日日躁夜夜躁夜夜| av免费观看日本| 久久久欧美国产精品| 夜夜骑夜夜射夜夜干| 69精品国产乱码久久久| 一区二区日韩欧美中文字幕|